Page 56 - ARNM-2-3

Advances in Radiotherapy &

Nuclear Medicine

ORIGINAL RESEARCH ARTICLE
Neoadjuvant chemoradiotherapy for T3N0M0

esophageal squamous cell carcinoma

1
Ying Liu 1† , Yehan Zhou 2† , Xiaoding Zhou , Jingqiu Li , Jie Zhu 1 , Yi Wang ,
1
1
Lei Wu , Gang Wan , Xuefeng Leng , Guangyuan Liu , Yongtao Han , Yang Liu ,
1
1
3
2
3
3
Lin Peng , and Qifeng Wang *
1
3
1 Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer
Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic
Science and Technology of China, Chengdu, Sichuan, China
2 Department of Pathology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital
and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science
and Technology of China, Chengdu, Sichuan, China
3 Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer
Hospital and Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic
Science and Technology of China, Chengdu, Sichuan, China
Abstract
The optimal treatment for patients with pretreatment T3N0M0 (pre-T3N0M0)
† These authors contributed equally esophageal squamous cell carcinoma (ESCC) remains controversial. This study
to this work. evaluated the impact of neoadjuvant chemoradiotherapy (NCRT) on the survival
*Corresponding author: outcomes of individuals diagnosed with pre-T3N0M0 ESCC. A total of 443 patients
Qifeng Wang with pre-T3N0M0 ESCC who underwent either NCRT plus surgery (NCRT + S)
(wangqifeng@scszlyy.org.cn) or surgery alone were included in the study. In the surgery group, patients with
Citation: Liu Y, Zhou Y, post-operative staging of pathological T3N0M0 (pT3N0M0) were classified as pre-
Zhou X, et al. Neoadjuvant T3N0M0. In the NCRT + S group, due to tumor downstaging after NCRT, patients
chemoradiotherapy for T3N0M0 with pre-treatment clinical T3 and post-operative pathology indicating lymph
esophageal squamous cell
carcinoma. Adv Radiother Nucl Med. nodes without evidence of tumor involvement or regression were considered to
2024;2(3):3821. have pre-T3N0M0. Univariate and multivariate Cox analyses were conducted to
doi: 10.36922/arnm.3821 identify independent prognostic factors influencing overall survival (OS) in pre-
Received: June 2, 2024 T3N0M0 patients. Kaplan–Meier curves were employed to assess disparities in OS
Accepted: July 8, 2024 and disease-free survival (DFS) between the two groups. Compared to surgery alone,
NCRT + S significantly enhanced the OS (Hazard ratio [HR] = 0.572, 95% Confidence
Published Online: September 11, interval [CI] = 0.407 – 0.804; P = 0.0059); however, it did not show a significant
2024
benefit in DFS (HR = 0.784, 95% CI = 0.564 – 1.09; P = 0.17). Compared with the
Copyright: © 2024 Author(s). surgery group, patients who achieved a pathologically complete response (pCR)
This is an Open-Access article
distributed under the terms of the after NCRT showed significantly improved OS (HR = 0.522, 95% CI = 0.339 – 0.804;
Creative Commons Attribution P = 0.019). The overall and locoregional recurrence rates were significantly lower in
License, permitting distribution, the NCRT + S group than in the surgery group. Compared with surgery alone, NCRT
and reproduction in any medium,
provided the original work is + S significantly improved OS in patients with pre-T3N0M0 stage disease, especially
properly cited. in those who achieved pCR after NCRT.
Publisher’s Note: AccScience
Publishing remains neutral with
regard to jurisdictional claims in Keywords: Esophageal cancer; Neoadjuvant chemoradiotherapy; Surgery; T3N0M0;
published maps and institutional Prognosis
affiliations

Volume 2 Issue 3 (2024) 1 doi: 10.36922/arnm.3821